Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.63 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
| ▸ | BCL9 | O00512 | 18/20 | 0.59 |
| ▸ | CTNNB1 | P35222 | 18/20 | 0.59 |
| ▸ | PDE5A | O76074 | 1/20 | 0.55 |
| ▸ | PDE1A | P54750 | 1/20 | 0.55 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.55 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20021965 | 0.91 | BCL9 (0.70) | BCL9CTNNB1 | |
| SCHEMBL20021945 | 0.83 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DBCL9 | |
| SCHEMBL20021971 | 0.82 | CTNNB1 (0.65) | BCL9CTNNB1 | |
| SCHEMBL20021946 | 0.81 | PDE4D (0.54) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL20021969 | 0.81 | BCL9 (0.79) | BCL9CTNNB1 | |
| SCHEMBL20021944 | 0.80 | MGLL (0.55) | — | |
| SCHEMBL20021967 | 0.78 | CTNNB1 (0.66) | BCL9CTNNB1 | |
| SCHEMBL20021968 | 0.78 | BCL9 (0.79) | BCL9CTNNB1 | |
| SCHEMBL7423277 | 0.77 | PDE4D (0.78) | PDE4APDE4BPDE4CPDE4DPDE5A | |
| SCHEMBL7340175 | 0.77 | PDE4D (1.00) | PDE4APDE4BPDE4CPDE4DPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092866-A1 | SUBSTITUTED N-([1,1'-BIPHENYL]-3-YL)-[1,1'-BIPHENYL]-3-CARBOXAMIDE ANALOGS AS INHIBITORS FOR BETA-CATENIN/B-CELL LYMPHOMA 9 INTERACTIONS | BCL9, BCL9L, BCL3 | PDE4A 4232/4885PDE4B 3680/4885PDE4C 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.